BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29929572)

  • 1. Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study.
    Tang J; Li XY; Liang JB; Wu D; Peng L; Li X
    Oncol Res; 2019 Jun; 27(6):635-641. PubMed ID: 29929572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
    Yang C; Feng W; Wu D
    J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
    Wu F; Zhang S; Gao G; Zhao J; Ren S; Zhou C
    Cancer Biol Ther; 2018 Mar; 19(3):141-144. PubMed ID: 29261000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
    Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
    Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Xu J; Liu X; Yang S; Shi Y
    Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
    Zhang D; Zhang C; Huang J; Guan Y; Guo Q
    Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
    Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
    Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
    Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
    Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
    JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
    Yu Z; Cai X; Xu Z; He Z; Lai J; Wang W; Zhang J; Kong W; Huang X; Chen Y; Shi Y; Shi X; Zhao Z; Ni M; Lin X; Chen S; Wu X; Chen W; Song Z; Huang C
    Oncologist; 2020 Nov; 25(11):e1640-e1649. PubMed ID: 32533785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
    Gandara DR; Leighl N; Delord JP; Barlesi F; Bennouna J; Zalcman G; Infante JR; Reckamp KL; Kelly K; Shepherd FA; Mazieres J; Janku F; Gardner OS; Mookerjee B; Wu Y; Cox DS; Schramek D; Peddareddigari V; Liu Y; D'Amelio AM; Blumenschein G
    J Thorac Oncol; 2017 Mar; 12(3):556-566. PubMed ID: 27876675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
    Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
    Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
    Leng J; Li DR; Huang LM; Ji XH; Wang DL
    Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
    Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
    Zhou C; Wang Y; Zhao J; Chen G; Liu Z; Gu K; Huang M; He J; Chen J; Ma Z; Feng J; Shi J; Yu X; Cheng Y; Yao Y; Chen Y; Guo R; Lin X; Wang Z; Gao G; Wang Q; Li W; Yang X; Wu L; Zhang J; Ren S
    Clin Cancer Res; 2021 Mar; 27(5):1296-1304. PubMed ID: 33323401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib plus docetaxel or pemetrexed shows promising activities against non-small cell lung cancer with brain metastasis: a retrospective analysis.
    Tang J; Jiang H; Xiang Z; Zhu X; Xie R; Wu D; Peng L; Li X
    J Thorac Dis; 2024 Jan; 16(1):615-622. PubMed ID: 38410538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
    Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.